Q-omics provides the consensus-scored PRELID3BP1 profile across patient tissues and cancer cell-line models. PRELID3BP1 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, PRELID3BP1 is differentially expressed in 5, with the highest sampling consensus in COAD. Additionally, PRELID3BP1 RNA expression shows 6,523 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRP, COAD, and STAD as cancer lineages where PRELID3BP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRELID3BP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRELID3BP1 survival associations across molecular data types. PRELID3BP1 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRELID3BP1 RNA expression–survival associations across cancer types. High PRELID3BP1 expression shows unfavorable associations in KIRP, KIRC, BRCA and SKCM, but favorable associations in BLCA and OV. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for PRELID3BP1 RNA expression.
This table summarizes PRELID3BP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for PRELID3BP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRELID3BP1 shows lower tumor expression in READ and higher tumor expression in COAD, UCEC, BLCA and LUSC. The COAD box plot shows higher PRELID3BP1 RNA expression in tumor versus normal tissue (log2 FC = +0.241, t-test p = .008).
This table shows molecular features associated with PRELID3BP1 in patient tissues and cancer cell lines. In patient samples, PRELID3BP1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
